<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prognosis of primary myelofibrosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prognosis of primary myelofibrosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prognosis of primary myelofibrosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard A Larson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H698341950"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) associated with bone marrow fibrosis, cytopenias, constitutional symptoms, hepatosplenomegaly, and/or extramedullary hematopoiesis. PMF has the least favorable prognosis among the MPNs, and patients are at risk for premature death due to disease progression, leukemic transformation, thrombo-hemorrhagic complications, and infections. PMF has previously been described by various names, including agnogenic myeloid metaplasia, myelofibrosis with myeloid metaplasia, and chronic idiopathic myelofibrosis.</p><p>This topic will discuss assessment of prognosis, which is important for evaluating potential clinical outcomes and for selecting treatment of PMF.</p><p>Clinical manifestations and diagnosis, risk-stratified management, and pathogenesis of PMF and an overview of MPNs are discussed separately. </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4511.html" rel="external">"Overview of the myeloproliferative neoplasms"</a>.)</p><p></p><p class="headingAnchor" id="H858468048"><span class="h1">CLINICAL OUTCOMES IN PMF</span><span class="headingEndMark"> — </span>PMF is the most aggressive of the BCR-ABL1-negative myeloproliferative neoplasms, which also includes polycythemia vera and essential thrombocythemia. PMF is associated with an estimated median overall survival (OS) of approximately six years [<a href="#rid1">1</a>]. As an example, median OS was 69 months (95% CI 61-76 months) in a multicenter retrospective study of 1054 patients diagnosed with PMF between 1980 and 2017 [<a href="#rid2">2</a>]. This study included patients who were managed with a wide variety of approaches, including observation, oral chemotherapy (primarily <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">hydroxyurea</a>), androgens, erythropoiesis-stimulating agents, steroids, interferon, <a class="drug drug_general" data-topicid="8593" href="/z/d/drug information/8593.html" rel="external">anagrelide</a>, immunomodulatory agents, splenectomy, and transplantation. Other prospective, retrospective, and population-based studies have reported comparable survival data [<a href="#rid3">3-11</a>].</p><p>Leukemic transformation is the most commonly identified cause of death in patients with PMF. In the multicenter study described above, transformation to acute leukemia accounted for 17 percent of deaths (86 of 517 deaths), followed by progression of PMF (10 percent), thrombosis and cardiovascular complications (7 percent), infection (6 percent), bleeding (3 percent), portal hypertension (2 percent), and second cancers (2 percent) [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H2669976559"><span class="h1">PROGNOSTIC FACTORS</span><span class="headingEndMark"> — </span>Clinical outcomes in PMF are associated with certain clinical factors and cytogenetic/molecular features.</p><p class="headingAnchor" id="H3599732785"><span class="h2">Clinical factors</span><span class="headingEndMark"> — </span>Outcomes in PMF are associated with age, presence of symptoms, blood counts, and other clinical and laboratory features, which have been incorporated into some prognostic models. The specific features and thresholds that are scored as adverse features for PMF vary from model to model. (See <a class="local">'Assessing prognosis in PMF'</a> below.)</p><p>Inferior survival in PMF is associated with the following clinical factors, based on multivariate analysis in large studies [<a href="#rid2">2,12-16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Older age</p><p class="bulletIndent1"><span class="glyph">●</span>Anemia</p><p class="bulletIndent1"><span class="glyph">●</span>Leukocytosis</p><p class="bulletIndent1"><span class="glyph">●</span>Thrombocytopenia</p><p class="bulletIndent1"><span class="glyph">●</span>Circulating blasts</p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow fibrosis</p><p class="bulletIndent1"><span class="glyph">●</span>Constitutional symptoms</p><p class="bulletIndent1"><span class="glyph">●</span>Need for transfusion</p><p></p><p>Inferior leukemia-free survival (LFS) was associated with platelet count &lt;100,000/microL and circulating blasts ≥2 percent by multivariate analysis in a study of 641 patients with PMF [<a href="#rid17">17</a>].</p><p>Expression of various cytokines is increased in PMF. Inferior overall survival (OS) and progression-free survival (PFS) were associated with elevated levels of interleukin (IL)-8 and IL-2R in a study of 127 treatment-naïve patients with PMF [<a href="#rid18">18</a>]. C-reactive protein &gt;7 mg/L was associated with inferior LFS in a separate study of 184 patients with PMF or myelofibrosis arising after other myeloproliferative neoplasms [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H2624947595"><span class="h2">Genetics</span></p><p class="headingAnchor" id="H286939650"><span class="h3">Cytogenetic features</span><span class="headingEndMark"> — </span>Cytogenetic abnormalities are common in PMF, but highly variable. The largest study of PMF reported an abnormal karyotype in 45 percent of 1002 patients at the time of diagnosis [<a href="#rid14">14</a>]. Certain cytogenetic features are independently associated with OS in PMF, and they have been grouped into three risk categories for use in prognostic models [<a href="#rid17">17,20-23</a>] (see <a class="local">'Assessing prognosis in PMF'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Very high risk (VHR): single or multiple abnormalities of -7, i(17q), inv(3)/3q21, 12p-/12p11.2, 11q-/11q23, or other autosomal trisomies not including +8/+9 (eg, +21, +19)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Favorable: normal karyotype or sole abnormalities of +9, 13q-, 20q-, chromosome 1 translocation/duplication, or sex chromosome abnormality including -Y</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unfavorable: all other abnormalities</p><p></p><p>Multivariate analysis of 641 patients with PMF (median age 63 years, 64 percent male) reported that, relative to the favorable category as a reference value, these cytogenetic categories were associated with the following hazard ratios (HR) for OS and LFS [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>VHR: OS HR 2.5 (95% CI 1.7-3.5); LFS HR 2.4 (95% CI 1.02-5.5)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unfavorable: OS HR 1.9 (95% CI 1.4-2.5); LFS HR 2.7 (95% CI 1.5-4.9)</p><p></p><p class="headingAnchor" id="H589517890"><span class="h3">Driver mutations</span><span class="headingEndMark"> — </span>Constitutive activation of the JAK/STAT pathway appears to be important to the pathogenesis of PMF, and mutations of three genes involved with this pathway, <em>JAK2 </em>(Janus kinase 2)<em>, CALR </em>(calreticulin)<em>, </em>and<em> MPL </em>(myeloproliferative leukemia virus oncogene, which encodes the thrombopoietin receptor) have been identified as drivers of this malignancy. (See  <a class="medical medical_review" href="/z/d/html/4526.html" rel="external">"Pathogenetic mechanisms in primary myelofibrosis", section on 'JAK/STAT pathway'</a>.)</p><p>Approximately 90 percent of patients with PMF have one of the following, mutually exclusive driver mutations [<a href="#rid17">17,20,24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2</em>: 57 to 65 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>CALR</em>: 20 to 25 percent</p><p class="bulletIndent1"><span class="glyph">●</span><em>MPL</em>: 5 to 10 percent</p><p class="bulletIndent1"><span class="glyph">●</span>"Triple-negative" (ie, none of the driver mutations): 10 to 12 percent</p><p></p><p>Clinical outcomes are generally best for <em>CALR</em>-mutated disease and worst for triple-negative disease. In a retrospective study of 428 patients with PMF, median OS for patients with a mutation of <em>JAK2</em>, <em>CALR</em>, <em>MPL</em>, or triple-negative disease were 5.9, 15.9, 9.9, and 2.3 years, respectively [<a href="#rid1">1</a>]. In another study of 641 patients, multivariate analysis reported the following HRs for OS; none of these factors was independently associated with LFS [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>JAK2</em>: 2.2 (95% CI 1.6-3.0)</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of type 1-like <em>CALR</em>: 2.0 (95% CI 1.5-2.8)</p><p class="bulletIndent1"><span class="glyph">●</span><em>MPL</em>: 1.6 (95% CI 1.1-2.6)</p><p class="bulletIndent1"><span class="glyph">●</span>Triple negative: 2.3 (95% CI 1.5-3.5)</p><p></p><p class="headingAnchor" id="H3517636098"><span class="h3">High molecular risk (HMR) mutations</span><span class="headingEndMark"> — </span>Mutations of certain genes are considered to be high molecular risk (HMR) mutations for PMF, and inferior outcomes are related to the number of HMR mutations.</p><p>More than 80 percent of patients with PMF harbor a variant of at least one of the following genes [<a href="#rid20">20,22,24</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><em>ASXL1</em> (38 percent)</p><p class="bulletIndent1"><span class="glyph">●</span><em>SRSF2 </em>(14 percent)</p><p class="bulletIndent1"><span class="glyph">●</span><em>U2AF1</em>Q157 (8 percent)</p><p class="bulletIndent1"><span class="glyph">●</span><em>EZH2 </em>(7 percent)</p><p class="bulletIndent1"><span class="glyph">●</span><em>IDH1/2 </em>(4 percent)</p><p></p><p>Several studies have reported that a greater number of HMR mutations is associated with increasingly poor prognosis [<a href="#rid20">20,22,24</a>]. As an example, in a study of 797 patients with PMF, median survivals for those with none, one, or two or more mutations in these genes, were 12.3, 7.0, and 2.6 years, respectively [<a href="#rid24">24</a>].</p><p>Multivariate analysis of 641 patients reported that mutations of <em>ASXL1</em>, <em>SRSF2</em>, and <em>U2AF1</em>Q157 were associated with inferior survival in PMF; HRs ranged from 1.6 to 2.2 [<a href="#rid17">17</a>]. <em>ASXL1</em> and <em>SRSF2 </em>were also independently associated with inferior LFS (HR: 2.1 and 4.3, respectively). Loss of heterozygosity for <em>TP53</em> was associated with leukemic transformation in a study that included 34 patients with PMF [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H3769792940"><span class="h1">ASSESSING PROGNOSIS IN PMF</span><span class="headingEndMark"> — </span>There is no consensus regarding the optimal prognostic tool for PMF, and the preferred model may vary by clinician and/or institution. In general, prognostic models that incorporate cytogenetic and molecular features are more effective for distinguishing risk groups than those that utilize clinical features alone. In settings where molecular techniques are not available, it is acceptable to use models that are based solely on clinical features and/or karyotype. (See <a class="local">'Alternative approaches'</a> below.)</p><p class="headingAnchor" id="H1242677699"><span class="h2">Our preferred approach</span><span class="headingEndMark"> — </span>We favor a two-step approach for assessing prognosis in PMF  (<a class="graphic graphic_algorithm graphicRef120377" href="/z/d/graphic/120377.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>We initially assess patients using GIPSS (genetically inspired prognostic scoring system) (<a class="calc calc_professional" href="/z/d/html/121355.html" rel="external">calculator 1</a>), an easy-to-use tool that requires only cytogenetic and molecular data [<a href="#rid17">17</a>]. GIPSS stratifies patients into four distinct prognostic groups (ie, low, intermediate [int]-1, int-2, high risk). (See <a class="local">'GIPSS'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients assigned to the GIPSS int-1 or int-2 categories (approximately two-thirds of patients), we suggest further evaluation with MIPSS70+ v2.0 (mutation-enhanced international prognostic scoring system plus karyotype, 70+, version 2.0) [<a href="#rid26">26</a>]. MIPSS70+ v2.0 is a more complex tool that incorporates clinical, cytogenetic, and molecular features, but it provides greater discrimination for patients with intermediate prognostic risk. MIPSS70+ v2.0 scoring is described below. (See <a class="local">'MIPSS70+ v2.0'</a> below.)</p><p></p><p>We prefer this two-step approach because it leverages the simplicity of GIPSS for identifying patients who are at highest and lowest risk for death and transformation to leukemia. GIPSS and MIPSS70+ v2.0 are equally effective for identifying patients in the highest and lowest risk categories [<a href="#rid17">17</a>].</p><p>In contrast, MIPSS70+ v2.0 is more effective for stratifying patients with intermediate prognosis, and it reclassifies substantial proportions of GIPSS int-1 and int-2 patients. As examples, GIPSS int-1 patients may be reassigned to MIPSS70+ v2.0 low, intermediate, or high risk groups, while GIPSS int-2 may be reassigned as MIPSS70+ v2.0 very high, high, or intermediate risk [<a href="#rid17">17</a>]. Reclassification of GIPSS int-1 or int-2 may have a significant effect on therapeutic decisions, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF", section on 'Risk stratification'</a>.)</p><p>Some clinicians may favor initial use of MIPSS70+ v2.0 for all patients (ie, rather than sequential application of GIPSS and MIPSS70+ v2.0). (See <a class="local">'MIPSS70+ v2.0'</a> below.)</p><p class="headingAnchor" id="H3751753823"><span class="h2">GIPSS</span><span class="headingEndMark"> — </span>GIPSS (genetically inspired prognostic scoring system) (<a class="calc calc_professional" href="/z/d/html/121355.html" rel="external">calculator 1</a>) is our preferred tool for initial assessment of prognosis in PMF. (See <a class="local">'Our preferred approach'</a> above.)</p><p>GIPSS is an easy-to-use prognostic tool that is based entirely on the karyotype and a limited number of mutations (ie, GIPSS does not include any clinical features) [<a href="#rid17">17</a>]. GIPSS has been validated for predicting overall survival (OS) and leukemia-free survival (LFS) in large patient populations, for which it was shown to be noninferior to other PMF prognostic models.</p><p>Importantly, for patients who are scored in one of the GIPSS intermediate (int) categories, we suggest subsequent application of the MIPSS70+ v2.0 prognostic model  (<a class="graphic graphic_algorithm graphicRef120377" href="/z/d/graphic/120377.html" rel="external">algorithm 1</a>). (See <a class="local">'MIPSS70+ v2.0'</a> below.)</p><p>GIPSS utilizes the following features:</p><p class="bulletIndent1"><span class="glyph">●</span>Karyotype<strong> </strong>(definitions of these categories are provided above) (see <a class="local">'Cytogenetic features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very high risk (VHR) = 2 points</p><p class="bulletIndent2"><span class="glyph">•</span>Unfavorable = 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Driver mutations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of type 1-like <em>CALR </em>= 1 point</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High molecular risk (HMR) mutations:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>ASXL1</em> mutation =1 point</p><p class="bulletIndent2"><span class="glyph">•</span><em>SRSF2</em> mutation = 1 point</p><p class="bulletIndent2"><span class="glyph">•</span><em>U2AF1</em>Q157 mutation = 1 point</p><p></p><p>Points are summed to assign a patient to one of four prognostic groups with distinct five-year OS and median OS (respectively, in parentheses), according to an international study of 641 patients [<a href="#rid17">17</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low risk</strong>: zero points (94 percent, 26.4 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Int-1</strong>: 1 point (73 percent, 10.3 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Int-2</strong>: 2 points (40 percent, 4.6 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>High risk</strong>: ≥3 points (14 percent, 2.6 years)</p><p></p><p>GIPSS scoring was comparable to MIPSS70+ v2.0 for prediction of 10-year mortality, based on logistic regression by area under the curve (AUC) analysis and Akaike information criterion (AIC) [<a href="#rid17">17</a>]; both GIPSS and MIPSS70+ v2.0 were superior to DIPSS (dynamic international prognostic scoring system) by these criteria.</p><p class="headingAnchor" id="H3754305714"><span class="h2">MIPSS70+ v2.0</span><span class="headingEndMark"> — </span>We suggest using MIPSS70+ v2.0 (mutation-enhanced international prognostic scoring system plus karyotype, version 2.0) (<a class="calc calc_professional" href="/z/d/html/121059.html" rel="external">calculator 2</a>) to refine the prognosis of patients who are assigned the GIPSS int-1 or int-2 categories  (<a class="graphic graphic_algorithm graphicRef120377" href="/z/d/graphic/120377.html" rel="external">algorithm 1</a>), as described above. Some clinicians may favor initial use of MIPSS70+ v2.0 for all patients with PMF. (See <a class="local">'Our preferred approach'</a> above.)</p><p>MIPSS70+ v2.0 is a more complex model that utilizes three clinical risk factors, five HMR mutations, and absence of type 1-like <em>CALR </em>mutation to stratify patients into five risk categories [<a href="#rid26">26</a>]. Sequential application of MIPSS70+ v2.0 to patients of intermediate risk is described above.</p><p>MIPSS70+ v2.0 utilizes the following features, and assigns points as follows [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical risk factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Severe anemia (Men: hemoglobin [Hb] &lt;9 g/dL; women: Hb &lt;8 g/dL): 2 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Moderate anemia (Men: Hb 9 to 10.9 g/dL; women: Hb 8 to 9.9 g/dL): 1 point</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Circulating blasts ≥2 percent: 1 point</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Constitutional symptoms: 2 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Karyotype (see <a class="local">'Cytogenetic features'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Very high risk (VHR): 4 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Unfavorable: 3 points</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mutations (see <a class="local">'High molecular risk (HMR) mutations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>≥2 high molecular risk (HMR) mutations: 3 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One HMR mutation: 2 points</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Absence of type 1-like <em>CALR</em>: 2 points</p><p></p><p>Points are summed to assign a patient to one of five MIPSS70+ v2.0 prognostic categories with distinct 10-year OS and median OS, based on a cohort study of 406 patients [<a href="#rid26">26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Very low risk: 0 points (86 percent, not reached)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low risk: 1 to 2 points (50 percent, 10.3 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate risk: 3 to 4 points (30 percent, 7 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>High risk: 5 to 8 points (10 percent, 3.5 years)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Very high risk: ≥9 points (&lt;3 percent, 1.8 years)</p><p></p><p>Compared with previous versions of this model (ie, MIPSS70 and MIPSS70-Plus), MIPSS70+ v2.0 established an additional prognostic category (ie, very high risk), to which one-sixth of patients were assigned without compromising the predictive power of the model [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H222110167"><span class="h2">Alternative approaches</span></p><p class="headingAnchor" id="H1599834635"><span class="h3">Why select an alternative approach?</span><span class="headingEndMark"> — </span>As discussed above, we favor prognostic tools that incorporate cytogenetic and molecular features, because they are the most effective models for risk stratification in PMF. (See <a class="local">'Our preferred approach'</a> above.)</p><p>Although tools that utilize only clinical and/or cytogenetic features are not as effective for stratifying patients into prognostic groups as our preferred models (ie, GIPSS and MIPSS70+ v2.0) [<a href="#rid17">17,26</a>], alternative models are acceptable in the following settings:</p><p class="bulletIndent1"><span class="glyph">●</span>If molecular analysis is not available, we favor use of DIPSS-Plus. (See <a class="local">'DIPSS-Plus'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If neither cytogenetics nor molecular analysis is available, DIPSS is an acceptable prognostic model. (See <a class="local">'DIPSS'</a> below.)</p><p></p><p class="headingAnchor" id="H1131679013"><span class="h3">DIPSS</span><span class="headingEndMark"> — </span>Dynamic international prognostic scoring system (DIPSS) is our preferred prognostic tool in settings where neither cytogenetics nor molecular analysis is available. DIPSS is based entirely on clinical features (age, leukocyte count, hemoglobin, circulating blasts, constitutional symptoms) [<a href="#rid27">27</a>]. DIPSS is a dynamic tool, meaning that it can be applied at any time in the course of PMF (ie, not only at the time of diagnosis). DIPSS differs from IPSS, an earlier prognostic tool, in that it assigns greater weight to severe anemia, based on its greater hazard ratio for survival when compared with the other clinical features [<a href="#rid2">2,27</a>].</p><p>DIPSS was created from a database of 525 patients with PMF, and reported the following median values for OS [<a href="#rid27">27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk: not reached </p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate-1: 14.2 years</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate-2: 4 years</p><p class="bulletIndent1"><span class="glyph">●</span>High risk: 1.5 years</p><p></p><p>DIPSS also effectively stratifies these categories for progression to leukemia [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H420216389"><span class="h3">DIPSS-Plus</span><span class="headingEndMark"> — </span>DIPSS-Plus  (<a class="graphic graphic_table graphicRef105009" href="/z/d/graphic/105009.html" rel="external">table 1</a>) is our preferred prognostic tool in settings where molecular analysis is not available [<a href="#rid13">13</a>]. DIPSS-Plus differs from DIPSS in that it adds three additional prognostic features (ie, transfusion-requiring anemia, unfavorable karyotype, and platelet count &lt;100,000/microL).</p><p>DIPSS-Plus was evaluated in 793 patients with PMF  (<a class="graphic graphic_figure graphicRef104430" href="/z/d/graphic/104430.html" rel="external">figure 1</a>), and reported the following values for median OS [<a href="#rid13">13</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Low risk: 185 months</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate-1: 78 months</p><p class="bulletIndent1"><span class="glyph">●</span>Intermediate-2: 35 months</p><p class="bulletIndent1"><span class="glyph">●</span>High risk: 16 months</p><p></p><p>DIPSS-Plus is inferior to both GIPSS and MIPSS70+ v2.0 for discriminating between PMF prognostic categories [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H2854367056"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H2015187593"><span class="h2">Younger patients</span><span class="headingEndMark"> — </span>There is no consensus regarding what constitutes a young patient in this setting, but PMF generally presents in middle-aged or older adults; one study reported that less than 10 percent of patients with PMF were ≤50 years old [<a href="#rid4">4</a>]. Few studies have focused exclusively on younger patients, but many large studies of PMF have identified younger age (generally &lt;65 years old) as a favorable prognostic factor for survival in PMF [<a href="#rid1">1-4,10,12-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/4529.html" rel="external">"Clinical manifestations and diagnosis of primary myelofibrosis", section on 'Epidemiology'</a>.)</p><p>We favor the approach described above to evaluate prognosis in younger patients with PMF. No studies have applied contemporary prognostic models (eg, GIPSS, MIPSS70+ v2.0) exclusively to populations of younger patients, but most large studies of PMF included patients ≤70 years old (eg, MIPSS70, MIPSS70-Plus, MIPSS70+ v2.0) [<a href="#rid16">16,26,28</a>]. (See <a class="local">'Our preferred approach'</a> above.)</p><p>One study of 123 patients &lt;55 years old reported 128 month median survival (95% CI 90-172 months) [<a href="#rid5">5</a>]. This study identified hemoglobin &lt;10 g/dL, presence of constitutional symptoms, and circulating blasts ≥1 percent as independent features associated with inferior survival, but it did not include cytogenetic and molecular findings. Using those criteria, two categories were described: Low risk (one adverse factor) had median survival of 176 months, and high risk (two or three factors) had a median survival of 33 months.</p><p class="headingAnchor" id="H858468797"><span class="h2">Prognosis in transplantation for PMF</span><span class="headingEndMark"> — </span>Allogeneic hematopoietic cell transplantation (HCT) is the only potentially curative therapy for PMF. Prognostic variables associated with outcomes for patients who undergo allogeneic HCT for PMF are described separately. (See  <a class="medical medical_review" href="/z/d/html/4531.html" rel="external">"Myelofibrosis (MF): Management of primary MF and secondary MF", section on 'Transplant-eligible patients'</a>.)</p><p class="headingAnchor" id="H858468845"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>There is scant information concerning the management and prognosis of pregnant women with PMF. Fetal mortality is high, although some pregnancies have been brought to term [<a href="#rid29">29-31</a>].</p><p class="headingAnchor" id="H1097019929"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) that manifests as bone marrow fibrosis, cytopenias, constitutional symptoms, hepatosplenomegaly, and/or extramedullary hematopoiesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Survival</strong> – PMF has an estimated median overall survival (OS) of approximately six years and is associated with the least favorable prognosis among the <em>BCR::ABL1</em>-negative MPNs, which also include polycythemia vera and essential thrombocythemia. Patients with PMF are at risk for premature death due to disease progression, leukemic transformation, thrombo-hemorrhagic complications, and infections. (See <a class="local">'Clinical outcomes in PMF'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic factors</strong> – Both clinical and molecular features are associated with prognosis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical</strong> – Inferior survival in PMF is associated with certain clinical prognostic factors, including older age, constitutional symptoms (ie, fever, sweats, weight loss), anemia, leukocytosis, thrombocytopenia, circulating blasts, the degree of bone marrow fibrosis, and transfusion dependence. (See <a class="local">'Clinical factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Genetic</strong> – Prognosis in PMF is also influenced by specific cytogenetic features, driver mutations (ie, <em>JAK2, CALR, MPL</em>), and certain high molecular risk (HMR) mutations (eg, <em>ASXL1</em>, <em>SRSF2</em>, <em>U2AF1</em>Q157<em>, EZH2, IDH1/2).</em> (See <a class="local">'Genetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment of prognosis</strong> – Our preferred approach  (<a class="graphic graphic_algorithm graphicRef120377" href="/z/d/graphic/120377.html" rel="external">algorithm 1</a>) for evaluating prognosis in PMF is to initially assess patients using GIPSS (genetically inspired prognostic scoring system) (<a class="calc calc_professional" href="/z/d/html/121355.html" rel="external">calculator 1</a>), an easy-to-use tool that utilizes only cytogenetic and molecular data. GIPSS stratifies patients into four prognostic groups: low, intermediate (int)-1, int-2, and high risk. For patients who are assigned to either GIPSS int-1 or int-2, we suggest subsequently evaluating the patient with MIPSS70+ v2.0 (mutation-enhanced international prognostic scoring system) (<a class="calc calc_professional" href="/z/d/html/121059.html" rel="external">calculator 2</a>), which incorporates clinical, cytogenetic, and molecular features. (See <a class="local">'Our preferred approach'</a> above.)</p><p></p><p class="bulletIndent1">We prefer this two-step approach because GIPSS is a simple and effective tool for identifying patients who are at highest and lowest risk for death and transformation to leukemia. However, MIPSS70+ v2.0 is more effective at stratifying risk for patients of intermediate prognosis, and it reclassifies a significant percentage of GIPSS int-1 and int-2 patients, which may affect treatment decisions. (See <a class="local">'GIPSS'</a> above and <a class="local">'MIPSS70+ v2.0'</a> above.)</p><p></p><p class="bulletIndent1">Use of MIPSS70+ v2.0 alone for all patients with PMF is an acceptable option for determining prognosis. (See <a class="local">'MIPSS70+ v2.0'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative approaches</strong> – Other methods to assess prognosis are acceptable in the following settings (see <a class="local">'Why select an alternative approach?'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If neither cytogenetics nor molecular analysis is available, DIPSS, which utilizes clinical features only, is an acceptable prognostic model. (See <a class="local">'DIPSS'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If molecular analysis is not available, we favor use of DIPSS-Plus. (See <a class="local">'DIPSS-Plus'</a> above.)</p><p></p><p class="headingAnchor" id="H3153392707"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The editors of UpToDate acknowledge the contributions of Stanley L Schrier, MD as Section Editor on this topic, his tenure as the founding Editor-in-Chief for UpToDate in Hematology, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014; 124:2507.</a></li><li><a class="nounderline abstract_t">Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113:2895.</a></li><li><a class="nounderline abstract_t">Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. Am J Hematol 1999; 61:10.</a></li><li><a class="nounderline abstract_t">Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88:1013.</a></li><li><a class="nounderline abstract_t">Cervantes F, Barosi G, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102:684.</a></li><li><a class="nounderline abstract_t">Dingli D, Schwager SM, Mesa RA, et al. Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system. Cancer 2006; 106:623.</a></li><li><a class="nounderline abstract_t">Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res 2007; 31:1503.</a></li><li><a class="nounderline abstract_t">Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109:2083.</a></li><li><a class="nounderline abstract_t">Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008; 111:1862.</a></li><li><a class="nounderline abstract_t">Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol 2009; 27:5587.</a></li><li><a class="nounderline abstract_t">Morel P, Duhamel A, Hivert B, et al. Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients. Blood 2010; 115:4350.</a></li><li><a class="nounderline abstract_t">Passamonti F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116:2857.</a></li><li><a class="nounderline abstract_t">Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392.</a></li><li><a class="nounderline abstract_t">Hussein K, Pardanani AD, Van Dyke DL, et al. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis. Blood 2010; 115:496.</a></li><li><a class="nounderline abstract_t">Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25:82.</a></li><li><a class="nounderline abstract_t">Guglielmelli P, Lasho TL, Rotunno G, et al. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol 2018; 36:310.</a></li><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Nicolosi M, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia 2018; 32:1631.</a></li><li><a class="nounderline abstract_t">Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29:1356.</a></li><li><a class="nounderline abstract_t">Barbui T, Carobbio A, Finazzi G, et al. Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis. Leukemia 2013; 27:2084.</a></li><li><a class="nounderline abstract_t">Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27:1861.</a></li><li><a class="nounderline abstract_t">Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28:1472.</a></li><li><a class="nounderline abstract_t">Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv 2016; 1:105.</a></li><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Lasho TL, et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; 28:1494.</a></li><li><a class="nounderline abstract_t">Guglielmelli P, Lasho TL, Rotunno G, et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 2014; 28:1804.</a></li><li><a class="nounderline abstract_t">Lundberg P, Karow A, Nienhold R, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123:2220.</a></li><li><a class="nounderline abstract_t">Tefferi A, Guglielmelli P, Lasho TL, et al. MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis. J Clin Oncol 2018; 36:1769.</a></li><li><a class="nounderline abstract_t">Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115:1703.</a></li><li><a class="nounderline abstract_t">Tefferi A, Nicolosi M, Mudireddy M, et al. Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. Leukemia 2018; 32:1189.</a></li><li><a class="nounderline abstract_t">Taylor UB, Bardeguez AD, Iglesias N, Gascon P. Idiopathic myelofibrosis in pregnancy: a case report and review of the literature. Am J Obstet Gynecol 1992; 167:38.</a></li><li><a class="nounderline abstract_t">Gotić M, Cvetković M, Bozanović T, Cemerikić V. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon]. Srp Arh Celok Lek 2001; 129:304.</a></li><li><a class="nounderline abstract_t">Tulpule S, Bewley S, Robinson SE, et al. The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Br J Haematol 2008; 142:480.</a></li></ol></div><div id="topicVersionRevision">Topic 104860 Version 14.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25037629" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18988864" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10331505" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8704209" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722294" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16369987" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prognosis in transplant-eligible patients with agnogenic myeloid metaplasia: a simple CBC-based scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17397921" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17407134" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18029552" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19786661" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308601" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20947690" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21149668" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901264" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20944670" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29226763" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29654267" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300928" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23828261" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23619563" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mutations and prognosis in primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402162" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29296803" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Targeted deep sequencing in primary myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24496303" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24549259" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24478400" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29708808" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20008785" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29472717" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442951" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Idiopathic myelofibrosis in pregnancy: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11928616" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18492097" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The management and outcome of four pregnancies in women with idiopathic myelofibrosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
